216 related articles for article (PubMed ID: 34797699)
1. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
Jain P; Zhao S; Lee HJ; Hill HA; Ok CY; Kanagal-Shamanna R; Hagemeister FB; Fowler N; Fayad L; Yao Y; Liu Y; Moghrabi OB; Navsaria L; Feng L; Nogueras Gonzalez GM; Xu G; Thirumurthi S; Santos D; Iliescu C; Tang G; Medeiros LJ; Vega F; Avellaneda M; Badillo M; Flowers CR; Wang L; Wang ML
J Clin Oncol; 2022 Jan; 40(2):202-212. PubMed ID: 34797699
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S
Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
Buske C; Tedeschi A; Trotman J; García-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS; Heffner LT; Varettoni M; Palomba ML; Shustik C; Kastritis E; Treon SP; Ping J; Hauns B; Arango-Hisijara I; Dimopoulos MA
J Clin Oncol; 2022 Jan; 40(1):52-62. PubMed ID: 34606378
[TBL] [Abstract][Full Text] [Related]
4. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
Jain P; Romaguera J; Srour SA; Lee HJ; Hagemeister F; Westin J; Fayad L; Samaniego F; Badillo M; Zhang L; Nastoupil L; Kanagal-Shamanna R; Fowler N; Wang ML
Br J Haematol; 2018 Aug; 182(3):404-411. PubMed ID: 29785709
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Wang ML; Jurczak W; Jerkeman M; Trotman J; Zinzani PL; Belada D; Boccomini C; Flinn IW; Giri P; Goy A; Hamlin PA; Hermine O; Hernández-Rivas JÁ; Hong X; Kim SJ; Lewis D; Mishima Y; Özcan M; Perini GF; Pocock C; Song Y; Spurgeon SE; Storring JM; Walewski J; Zhu J; Qin R; Henninger T; Deshpande S; Howes A; Le Gouill S; Dreyling M;
N Engl J Med; 2022 Jun; 386(26):2482-2494. PubMed ID: 35657079
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.
Tivey A; Shotton R; Eyre TA; Lewis D; Stanton L; Allchin R; Walter H; Miall F; Zhao R; Santarsieri A; McCulloch R; Bishton M; Beech A; Willimott V; Fowler N; Bedford C; Goddard J; Protheroe S; Everden A; Tucker D; Wright J; Dukka V; Reeve M; Paneesha S; Prahladan M; Hodson A; Qureshi I; Koppana M; Owen M; Ediriwickrema K; Marr H; Wilson J; Lambert J; Wrench D; Burney C; Knott C; Talbot G; Gibb A; Lord A; Jackson B; Stern S; Sutton T; Webb A; Wilson M; Thomas N; Norman J; Davies E; Lowry L; Maddox J; Phillips N; Crosbie N; Flont M; Nga E; Virchis A; Camacho RG; Swe W; Pillai A; Rees C; Bailey J; Jones S; Smith S; Sharpley F; Hildyard C; Mohamedbhai S; Nicholson T; Moule S; Chaturvedi A; Linton K
Blood Adv; 2024 Mar; 8(5):1209-1219. PubMed ID: 38127279
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
Le Gouill S; Morschhauser F; Chiron D; Bouabdallah K; Cartron G; Casasnovas O; Bodet-Milin C; Ragot S; Bossard C; Nadal N; Herbaux C; Tessoulin B; Tchernonog E; Rossi C; McCulloch R; Gastinne T; Callanan MB; Rule S
Blood; 2021 Feb; 137(7):877-887. PubMed ID: 33181832
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
Wang ML; Lee H; Chuang H; Wagner-Bartak N; Hagemeister F; Westin J; Fayad L; Samaniego F; Turturro F; Oki Y; Chen W; Badillo M; Nomie K; DeLa Rosa M; Zhao D; Lam L; Addison A; Zhang H; Young KH; Li S; Santos D; Medeiros LJ; Champlin R; Romaguera J; Zhang L
Lancet Oncol; 2016 Jan; 17(1):48-56. PubMed ID: 26640039
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Wang ML; Jain P; Zhao S; Lee HJ; Nastoupil L; Fayad L; Ok CY; Kanagal-Shamanna R; Hill HA; Yao Y; Hagemeister FB; Westin JR; Fowler N; Samaniego F; Steiner R; Nair R; Iyer SP; Navsaria L; Badillo M; ; Feng L; Xuelin H; Nogueras Gonzalez GM; Xu G; Wagner-Bartak N; Thirumurthi S; Santos D; Tang G; Lin P; Wang SA; Jorgensen J; Yin CC; Li S; Patel KP; Vega F; Medeiros LJ; Flowers CR; Wang L
Lancet Oncol; 2022 Mar; 23(3):406-415. PubMed ID: 35074072
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
Giné E; de la Cruz F; Jiménez Ubieto A; López Jimenez J; Martín García-Sancho A; Terol MJ; González Barca E; Casanova M; de la Fuente A; Marín-Niebla A; Muntañola A; González-López TJ; Aymerich M; Setoain X; Cortés-Romera M; Rotger A; Rodríguez S; Medina Herrera A; García Sanz R; Nadeu F; Beà S; Campo E; López-Guillermo A
J Clin Oncol; 2022 Apr; 40(11):1196-1205. PubMed ID: 35030036
[TBL] [Abstract][Full Text] [Related]
12. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS
J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
[TBL] [Abstract][Full Text] [Related]
14. Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
Ip A; Petrillo A; Della Pia A; Lee GG; Gill S; Varughese T; Zenreich J; Gutierrez M; Zhang J; Ahn J; Bharani V; Nejad AS; Pascual L; Feldman TA; Leslie LA; Goy AH
Leuk Lymphoma; 2023 Dec; 64(14):2225-2235. PubMed ID: 37740588
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
[TBL] [Abstract][Full Text] [Related]
16. Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
Kabadi SM; Byfield SD; LE L; Olufade T
Anticancer Res; 2021 Feb; 41(2):927-936. PubMed ID: 33517299
[TBL] [Abstract][Full Text] [Related]
17. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Fowler NH; Nastoupil L; De Vos S; Knapp M; Flinn IW; Chen R; Advani RH; Bhatia S; Martin P; Mena R; Davis RE; Neelapu SS; Eckert K; Ping J; Co M; Beaupre DM; Neuenburg JK; Palomba ML
Br J Haematol; 2020 May; 189(4):650-660. PubMed ID: 32180219
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
Goto H; Ito S; Kizaki M; Yamaguchi M; Fukuhara N; Kato K; Saito T; Terui Y; Okubo S; Soshin T; Zeng J; Honda H; Badawi M; Ross JA; Izutsu K
Int J Clin Oncol; 2024 Feb; 29(2):232-240. PubMed ID: 38157190
[TBL] [Abstract][Full Text] [Related]
19. A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
Cheung MC; Mittmann N; Owen C; Abdel-Samad N; Fraser GAM; Lam S; Crump M; Sperlich C; van der Jagt R; Prica A; Couban S; Woyach JA; Ruppert AS; Booth AM; Mandrekar SJ; McDonald G; Shepherd LE; Yen H; Chen BE; Hay AE
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):766-774. PubMed ID: 34334330
[TBL] [Abstract][Full Text] [Related]
20. Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.
Rai S; Tanizawa Y; Cai Z; Huang YJ; Taipale K; Tajimi M
Adv Ther; 2022 Oct; 39(10):4792-4807. PubMed ID: 35984628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
